歌礼制药-B公布小分子GLP-1R激动剂ASC30超长效皮下缓释制剂数据,在肥胖患者中观察半衰期达75天

美股速递
Sep 09, 2025

歌礼制药-B近日宣布,其研发的小分子GLP-1受体激动剂ASC30的超长效皮下缓释维持制剂在临床研究中取得重要进展。该制剂在肥胖参与者中显示出75天的观察半衰期,展现了其作为超长效治疗方案的巨大潜力。

这一研究结果表明,ASC30皮下缓释制剂具备了显著的药代动力学优势,其超长的半衰期有望为肥胖症患者提供更加便利的给药方案,减少注射频次,提高患者依从性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10